Lambda Therapeutic Research Acquires Novum Pharmaceutical Research Services

Velocity Clinical Research Acquires Omega Medical Research and Buynak Clinical Research

June 16, 2020

Healthcare Services

Durham-based Velocity Clinical Research has acquired Omega Medical Research (Providence, Rhode Island) and Buynak Clinical Research (Valparaiso, Indiana), expanding its multi-site footprint to 12 sites across nine states. The deals, together with a strategic partnership with Elite Research Network, are intended to boost Velocity’s capacity for vaccine and COVID-19 treatment trials while adding geographic and therapeutic diversity.

Catalyst Clinical Research Acquires Aptus Clinical

May 4, 2022

Healthcare Services

Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, has acquired U.K.-based Aptus Clinical to accelerate Catalyst's European expansion and broaden its oncology and early-phase clinical services. The deal creates a multi-region CRO operating across North America and Europe, increases Catalyst's patient reach by nearly 600 and lifts combined headcount to more than 800.

Sygnature Discovery Acquires NuChem Sciences

August 1, 2023

Biotechnology

UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.

Novartis Acquires Regulus Therapeutics

June 25, 2025

Biotechnology

Novartis has completed the acquisition of Regulus Therapeutics, making Regulus an indirect wholly owned subsidiary following a tender offer and merger. The deal secures Regulus' investigational oligonucleotide therapy farabursen for ADPKD and strengthens Novartis' renal disease pipeline.

ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

March 9, 2021

Pharmaceuticals

ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.

Novotech Acquires US-based Regulatory Consulting Firm CBR International

January 9, 2023

Healthcare Services

Novotech, an Asia-Pacific–focused clinical research organization (CRO), has acquired US-based regulatory and drug development consultancy CBR International. The acquisition strengthens Novotech's US FDA regulatory, scientific and clinical development capabilities to better support biotech and pharma clients across the US, Europe and Asia-Pacific.